Abstract
The extent of non-clinical safety testing to support clinical trials at different stages of development differed greatly between the EU, Japan and the USA prior to the adoption of the original ICH M3 guidance in 1997. The guideline achieved some notable harmonizations, but there was still significant disharmony, especially around the duration of dosing for non-rodents and the timing and extent of reproductive toxicology studies to support trials in women of childbearing potential. The inability to harmonise on these particular issues led to a reluctant acceptance of finalising the M3 guidance.
In 2006, a revision of ICH M3 commenced with an aim to remove the un-harmonised components. Although the M3 guideline is essentially concerned with the timing of non-clinical studies in relation to clinical development, further topics were also introduced by the Expert Working Group during the discussions. The ICH M3(R2) document was signed off by the regulators in June 2009. While the 2000 version of the guideline had 6 pages of text, the revision had 27. All the objectives had been largely met and with only one minor difference still in place.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
/20/EC. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities 1.5.2001. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF
CDER (2008) Guidance for industry. Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. Center for Drug Evaluation and Research, Feb 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=PPARguidance2008&utm_content=2
CPMP III/3824/92 Rev.1. Committee for Proprietary Medicinal Products. Applicability of good laboratory practice. Commission of the European Communities
EMEA/341972/2006. CHMP SWP reflection paper on PPAR’s (Peroxisome Proliferator Activated Receptors), Sept 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/11/WC500015479.pdf
Hayashi (1995) Duration of repeated dose studies to support first entry into humans. In: D’Arcy and Harron (eds) Proceedings of the third international conference on harmonization, Yokohama, pp 342–343
ICH M3 (1997) Nonclinical safety testing for the conduct of human for pharmaceuticals. ICH, July 1997. http://ocw.jhsph.edu/courses/drugdevelopment/PDFs/FDA_Guidance_on_NonCLinical_Safety_Studeis.pdf
ICH M3(R2) (2009) Guidance on nonclinical safety studies for the conduct of human clinical trials of and marketing authorization for pharmaceuticals. 11 June 2009. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
ICH S4 (1998) Duration of chronic toxicity testing in animals (rodents and non-rodents). 2 Sept 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S4/Step4/S4_Guideline.pdf
ICH S7A (2000) Safety pharmacology studies for human pharmaceuticals. 8 Nov 2000. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf
Mayahara (1995) Progress of the ICH guideline. In: D’Arcy and Harron (eds) Proceedings of the third international conference on harmonization, Yokohama, pp 339–342
National Centre for the Replacement, Refinement and Reduction of Animals in Research (2007) Challenging requirements for acute toxicity studies: Workshop report
Ohno (1991) Toxicity testing: regulatory perspectives. In: D’Arcy and Harron (eds) Proceedings of the first international conference on harmonization, Brussels, pp 186–188
Robinson S, Delongeas JL, Donald E, Dreher D, Festag M, Kervyn S, Lampo A, Nahas K, Nogues V, Ockert D, Quinn K, Old S, Pickersgill N, Somers K, Stark C, Stei P, Waterson L, Chapman K (2008) A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. Regul Toxicol Pharmacol 50:345–352
Sakai et al (2000) Collaborative work to evaluate toxicity in male reproductive organs by repeated dose studies in rats – overview of the studies. J Toxicol Sci 25:1–21
Sanbuissho A, Yoshida M, Hisada S, Sagami F, Kudo S, Kumazawa T, Ube M, Komatsu S, Ohno Y (2009) Collaborative work on evaluation of ovarian toxicity by repeated-dose and fertility studies in female rats. J Toxicol Sci 34:SP1–SP22
Scales (1992) Timing of toxicity studies vs conduct of clinical trials – existing requirements. In: D’Arcy and Harron (eds) Proceedings of the first international conference on harmonization, Brussels, pp 322–329
Sjöberg (1995) Data to support the extension of clinical trials. In: D’Arcy and Harron (eds) Proceedings of the third international conference on harmonization, Yokohama, pp 343–345
Takayama et al (1995) A collaborative study in Japan on optimal treatment period and parameters for detection of male fertility disorders induced by drugs in rats. J Am Coll Toxicol 14:266–292
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Sjöberg, P., Jones, D.R. (2013). Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2). In: van der Laan, J., DeGeorge, J. (eds) Global Approach in Safety Testing. AAPS Advances in the Pharmaceutical Sciences Series, vol 5. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5950-7_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5950-7_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5949-1
Online ISBN: 978-1-4614-5950-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)